Activin and Inhibin

JNJ-42226314 is a competitive, highly selective and reversible non-covalent monoacylglycerol lipase (MAGL) inhibitor. JNJ-42226314 demonstrates dose-dependent enhancement of the major endocannabinoid 2-arachidonoylglycerol (2-AG) as well as efficacy

JNJ-42226314 is a competitive, highly selective and reversible non-covalent monoacylglycerol lipase (MAGL) inhibitor. JNJ-42226314 demonstrates dose-dependent enhancement of the major endocannabinoid 2-arachidonoylglycerol (2-AG) as well as efficacy

JNJ-42226314 is a competitive, highly selective and reversible non-covalent monoacylglycerol lipase (MAGL) inhibitor. JNJ-42226314 demonstrates dose-dependent enhancement of the major endocannabinoid 2-arachidonoylglycerol (2-AG) as well as efficacy

JNJ-42226314 is a competitive, highly selective and reversible non-covalent monoacylglycerol lipase (MAGL) inhibitor. JNJ-42226314 demonstrates dose-dependent enhancement of the major endocannabinoid 2-arachidonoylglycerol (2-AG) as well as efficacy

JNJ-42253432 is a CNS-penetrant, high-affinity and orally active P2X7 antagonist, with pK i values of 9.1 and 7.9 for rat and human P2X7 channels, respectively.In VivoWhen dosed in rats, JNJ-42253432 occupied the brain P2X7 channel with an ED 50 of

JNJ-42253432 is a CNS-penetrant, high-affinity and orally active P2X7 antagonist, with pK i values of 9.1 and 7.9 for rat and human P2X7 channels, respectively.In VivoWhen dosed in rats, JNJ-42253432 occupied the brain P2X7 channel with an ED 50 of

JNJ-42253432 is a CNS-penetrant, high-affinity and orally active P2X7 antagonist, with pK i values of 9.1 and 7.9 for rat and human P2X7 channels, respectively.In VivoWhen dosed in rats, JNJ-42253432 occupied the brain P2X7 channel with an ED 50 of

JNJ-54175446 is a potent and selective brain penetrant P2X7 receptor antagonist, with pIC 50 s of 8.46 and 8.81 for hP2X7 receptor and rP2X7 receptor, respectively.In VitroJNJ-54175446 (Compound 14) is a potent and selective brain penetrant P2X7

JNJ-54175446 is a potent and selective brain penetrant P2X7 receptor antagonist, with pIC 50 s of 8.46 and 8.81 for hP2X7 receptor and rP2X7 receptor, respectively.In VitroJNJ-54175446 (Compound 14) is a potent and selective brain penetrant P2X7

JNJ-54175446 is a potent and selective brain penetrant P2X7 receptor antagonist, with pIC 50 s of 8.46 and 8.81 for hP2X7 receptor and rP2X7 receptor, respectively.In VitroJNJ-54175446 (Compound 14) is a potent and selective brain penetrant P2X7

JNJ-55308942 is a high-affinity, selective, brain-penetrant P2X7 functional antagonist (hP2X7: IC 50 =10 nM, K i =7.1 nM: rP2X7: IC 50 =15 nM, K i =2.9 nM). JNJ-55308942 is orally bioavailable, binds to brain P2X7 and blocks IL-1β release from adult

JNJ-55308942 is a high-affinity, selective, brain-penetrant P2X7 functional antagonist (hP2X7: IC 50 =10 nM, K i =7.1 nM: rP2X7: IC 50 =15 nM, K i =2.9 nM). JNJ-55308942 is orally bioavailable, binds to brain P2X7 and blocks IL-1β release from adult